MedTrace Logo

Sarcopenic Obesity in Liver Transplanted Patients

NCT05029713 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-05-10

No results posted yet for this study

Summary

The prevalence of obesity in cirrhotic patients who are candidates for liver transplantation (LT) is increasing, a phenomenon consistent with the increased prevalence of obesity in the general population. On the other hand, in liver patients on the waiting list for transplantation it is often observed sarcopenia. The combination of the two condition is defined sarcopenic obesity, which combines the negative synergy deriving from the two conditions. In this study the investigators will evaluate, for the first time, the prevalence of sarcopenic obesity in subjects undergone LT and determine the possible associated risk factors, particularly the role of immunosuppressive treatment with calcineurin inhibitors in addition to dietary habits and physical activity.

Conditions

  • Sarcopenic Obesity

Interventions

DIAGNOSTIC_TEST

Evaluation of appendicular skeletal muscle mass (ASMM) by bioelectrical impedance analysis (BIA)

The use of handgrip dynamometer and BIA will be used to screen all liver transplanted patients for sarcopenic obesity, using a muscle strength cut-off \<27 Kg in men and \<16 Kg in women and a standardized muscle mass cut-off \<0.789 ASMM/BMI for men and 0.512 ASMM/BMI for women.

Sponsors & Collaborators

  • Prof. Maria Grano

    collaborator UNKNOWN

  • University of Bari

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-10
Primary Completion
2023-10-30
Completion
2023-10-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05029713 on ClinicalTrials.gov